To include your compound in the COVID-19 Resource Center, submit it here.

CVT-510 meets Phase III endpoint

CV Therapeutics (CVTX) said a U.S. and U.K. Phase III trial of its

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE